Indo US Bio-Tech

Which are the latest news on Indo US Bio-Tech?

Why is Indo US Bio-Tech Ltd falling/rising?

As of 05-Sep, Indo US Bio-Tech Ltd's stock price is declining, currently at Rs. 79.50, with a recent 52-week low of Rs. 72.6 and a year-to-date return of -45.19%. The stock shows significant volatility and underperformance compared to its sector and the benchmark Sensex, indicating ongoing challenges for the company.

As of 05-Sep, Indo US Bio-Tech Ltd's stock price is falling, currently at Rs. 79.50, reflecting a decrease of Rs. 1.63 or 2.01%. The stock has recently hit a new 52-week low of Rs. 72.6 today, indicating significant downward pressure. Performance metrics reveal that the stock has underperformed its sector by 10.79% today and opened with a loss of 5.46%. Additionally, the stock has experienced high volatility, with an intraday volatility of 12.98%.<BR><BR>Over the past year, the stock has generated a return of -45.19%, significantly underperforming the benchmark Sensex, which has only declined by 5.21% during the same period. The stock's long-term growth prospects appear poor, with operating profit growing at an annual rate of only 16.23% over the last five years, and the company has reported negative results for the last three consecutive quarters. Furthermore, delivery volume has fallen sharply, down 65.04% against the five-day average, indicating declining investor interest.<BR><BR>Despite some positive factors, such as high management efficiency and a strong ability to service debt, the overall trend and recent performance suggest that the stock is facing significant challenges, leading to its current decline.

Who are in the management team of Indo US Bio-Tech?

The management team of Indo US Bio-Tech includes Jagdish Ajudia (Chairman & Managing Director), Maltiben Ajudia (Whole-time Director), Priyanka Ajudia (Executive Director), Ritaben Nileshbhai Kikani (Non-Executive & Independent Director), and Dimpy Joshi (Company Secretary).

The management team of Indo US Bio-Tech includes the following individuals:<BR><BR>1. **Jagdish Ajudia** - Chairman & Managing Director<BR>2. **Maltiben Ajudia** - Whole-time Director<BR>3. **Priyanka Ajudia** - Executive Director<BR>4. **Ritaben Nileshbhai Kikani** - Non-Executive & Independent Director<BR>5. **Dimpy Joshi** - Company Secretary<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Indo US Bio-Tech do?

Indo US Bio-Tech Ltd, a Micro Cap company in the Other Agricultural Products industry, was incorporated in 2004 and became a public company in 2018. As of June 2026, it reported net sales of 33 Cr and a net profit of 3 Cr, with a market cap of INR 169 Cr.

Overview:<BR>Indo US Bio-Tech Ltd operates in the Other Agricultural Products industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as "Pollucid Bio-Tech Private Limited" in 2004, underwent several name changes, and became "Indo US Bio-Tech Limited" upon conversion to a Public Limited Company in 2018. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 33 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 3 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 169 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 14.00 <BR>Industry P/E: 43 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.31 <BR>Return on Equity: 13.22% <BR>Price to Book: 1.91 <BR><BR>Contact Details:<BR>Address: 309 Shanti Mall, Satadhar Char Rasta Sola Road Ahmedabad Gujarat : 380061 <BR>Tel: 91-79-27491807 <BR>Email: compliance@indousagriseeds.com <BR>Website: http://www.indousagriseeds.com

Who are the peers of the Indo US Bio-Tech?

Indo US Bio-Tech's peers include Prime Fresh, MANGALAM SEEDS, Harshdeep Horti., JK Agri Genetics, Nag. Agri Tech., Kohinoor Foods, Sawaliya Food, and Shivashrit Foods, with varying management risks and growth rates. Kohinoor Foods has the highest 1-year return at -0.29%, while Indo US Bio-Tech has the lowest at -46.27%.

Peers: The peers of Indo US Bio-Tech are Prime Fresh, MANGALAM SEEDS, Harshdeep Horti., JK Agri Genetics, Nag. Agri Tech., Kohinoor Foods, Sawaliya Food, and Shivashrit Foods.<BR><BR>Quality Snapshot: Excellent management risk is observed at Harshdeep Horti. and the rest, while Good management risk is found at Indo US Bio-Tech, Sawaliya Food, and Shivashrit Foods. Average management risk is noted at Prime Fresh, MANGALAM SEEDS, and JK Agri Genetics, while Below Average management risk is present at Nag. Agri Tech. Kohinoor Foods does not qualify. Growth is Excellent at Sawaliya Food, Good at Prime Fresh, MANGALAM SEEDS, Harshdeep Horti., and Nag. Agri Tech., while Below Average growth is seen at Indo US Bio-Tech, JK Agri Genetics, and Shivashrit Foods. Average growth is noted at MANGALAM SEEDS. Capital Structure is Excellent at Harshdeep Horti., Good at Indo US Bio-Tech, Nag. Agri Tech., Sawaliya Food, and Shivashrit Foods, while Average is seen at MANGALAM SEEDS, and Below Average at JK Agri Genetics.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kohinoor Foods at -0.29%, while Indo US Bio-Tech has the lowest at -46.27%. This indicates that Indo US Bio-Tech's 1-year return is significantly worse than Kohinoor Foods. Additionally, peers with negative six-month returns include Indo US Bio-Tech, Harshdeep Horti., JK Agri Genetics, Nag. Agri Tech., and Shivashrit Foods.

How big is Indo US Bio-Tech?

As of 31st August, Indo US Bio-Tech Ltd has a market capitalization of 169.00 Cr, with recent net sales of 112.66 Cr and a net profit of 11.46 Cr. Shareholder's funds are 38.51 Cr, and total assets amount to 55.20 Cr as of March 2022.

As of 31st August, Indo US Bio-Tech Ltd has a market capitalization of 169.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 112.66 Cr and a Net Profit of 11.46 Cr.<BR><BR>The latest annual period for the balance sheet is March 2022, with Shareholder's Funds amounting to 38.51 Cr and Total Assets of 55.20 Cr.

Should I buy, sell or hold Indo US Bio-Tech Ltd?

Are Indo US Bio-Tech Ltd latest results good or bad?

Indo US Bio-Tech Ltd's latest Q4 FY26 results are concerning, with a 46.47% year-on-year decline in net profit and a 22.05% drop in revenue, alongside the lowest operating margin in seven quarters at 12.38%. Overall, these indicators suggest significant operational challenges and deteriorating financial performance.

Indo US Bio-Tech Ltd's latest results for Q4 FY26 indicate a challenging quarter for the company. The net profit decreased significantly to ₹1.97 crores, reflecting a decline of 46.47% year-on-year and a 34.33% drop compared to the previous quarter. Revenue also faced a substantial year-on-year decline of 22.05%, although there was a sequential improvement of 14.12% from the previous quarter.<BR><BR>Moreover, the operating margin fell to 12.38%, marking the lowest level in seven quarters and a significant drop from 23.51% in the same quarter last year. This margin compression, coupled with declining revenues, suggests that the company is experiencing operational stress and challenges in maintaining profitability.<BR><BR>Overall, the results are concerning, with multiple indicators showing deterioration in financial performance. The combination of declining profits, revenue volatility, and reduced margins paints a negative picture for the company's current operational health.

When is the next results date for Indo US Bio-Tech Ltd?

The next results date for Indo US Bio-Tech Ltd is January 21, 2026.

The next results date for Indo US Bio-Tech Ltd is scheduled for January 21, 2026.

Is Indo US Bio-Tech overvalued or undervalued?

As of December 4, 2025, Indo US Bio-Tech is considered very attractive and undervalued, with a PE ratio of 15.32, strong growth potential indicated by a PEG ratio of 0.35, and solid financial performance metrics, despite a year-to-date stock performance lagging behind the Sensex.

As of 4 December 2025, the valuation grade for Indo US Bio-Tech has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 15.32, an EV to EBITDA of 14.47, and a PEG ratio of 0.35, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Indo US Bio-Tech stands out with a significantly lower PE ratio than Jain Irrigation at 52.39 and Krishival Foods at 77.88, both of which are considered very expensive. Additionally, the company’s ROE of 19.48% and ROCE of 16.37% further reinforce its strong financial performance. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -59.05% compared to the Sensex's 9.12%, the underlying fundamentals suggest that Indo US Bio-Tech is positioned for recovery and growth.

How has been the historical performance of Indo US Bio-Tech?

Indo US Bio-Tech has shown steady growth over the past three years, with net sales increasing from 39.76 crore in March 2020 to 50.06 crore in March 2022, and profit after tax rising from 2.53 crore to 5.06 crore. Despite rising raw material costs, the company improved its operational efficiency and cash flow during this period.

Answer:<BR>The historical performance of Indo US Bio-Tech shows a steady growth in net sales and profit over the past three years.<BR><BR>Breakdown:<BR>Indo US Bio-Tech's net sales increased from 39.76 crore in March 2020 to 50.06 crore in March 2022, reflecting a positive trend in revenue generation. The total operating income followed the same trajectory, rising from 39.76 crore in March 2020 to 50.06 crore in March 2022. However, raw material costs surged significantly from 3.59 crore in March 2020 to 45.20 crore in March 2022, indicating increased operational expenses. Despite this, the operating profit (PBDIT) improved from 3.99 crore in March 2020 to 6.95 crore in March 2022, showcasing better operational efficiency. Profit before tax also rose from 2.86 crore in March 2020 to 5.31 crore in March 2022, while profit after tax increased from 2.53 crore to 5.06 crore in the same period. The company's total assets grew from 34.70 crore in March 2020 to 55.20 crore in March 2022, alongside a rise in total liabilities from 34.70 crore to 55.20 crore. Cash flow from operating activities showed a positive trend, moving from 0.00 crore in March 2021 to 2.00 crore in March 2022, indicating improved cash generation capabilities. Overall, Indo US Bio-Tech has demonstrated consistent growth in sales, profits, and asset accumulation over the past three years.

Who are the top shareholders of the Indo US Bio-Tech?

The top shareholder of Indo US Bio-Tech is Jagdishkumar Devjibhai Ajudiya, holding 48.82%. Other notable shareholders include Improwised Technologies Private at 1.99% and individual investors with a collective 24.34%.

The top shareholders of Indo US Bio-Tech include the promoters, with Jagdishkumar Devjibhai Ajudiya holding the largest share at 48.82%. There are no pledged promoter holdings, and the company does not have any mutual fund schemes invested in it. Additionally, there is one Foreign Institutional Investor (FII) with a very minimal holding of 0.0%. The highest public shareholder is Improwised Technologies Private, which holds 1.99%. Individual investors collectively hold 24.34% of the shares.

What is the technical trend for Indo US Bio-Tech?

As of May 26, 2025, the market trend is mildly bearish, with daily moving averages and weekly Bollinger Bands indicating bearish signals, despite some mixed indicators like the MACD and KST showing mild bullishness in the short term.

As of 26 May 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a bearish signal. The MACD presents a mixed picture with a mildly bullish signal on the weekly but mildly bearish on the monthly. The KST aligns with this by being mildly bullish weekly and mildly bearish monthly. The OBV is consistently mildly bearish across both time frames. Overall, while there are some mildly bullish indicators, the prevailing sentiment remains bearish, particularly in the short term.

What is the bonus history of the Indo US Bio-Tech?

Indo US Bio-Tech has a history of issuing bonus shares, with the most recent being a 1:1 bonus on August 29, 2023, following a 1:5 bonus on November 29, 2021, and a 1:4 bonus on April 23, 2019. This reflects the company's commitment to rewarding its shareholders.

Indo US Bio-Tech has a notable bonus history. The most recent bonus issue was a 1:1 bonus announced with an ex-date of August 29, 2023. Prior to that, the company issued a 1:5 bonus on November 29, 2021, and a 1:4 bonus on April 23, 2019. This shows a consistent approach to rewarding shareholders through bonus shares over the years.

Has Indo US Bio-Tech declared dividend?

Indo US Bio-Tech Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of December 3, 2024. Recent total returns have shown significant volatility, with a total return of -42.67% over the last 6 months, but positive long-term returns over 2, 3, 4, and 5 years.

Indo US Bio-Tech Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: ₹0.20<BR>- Ex-date: 03 Dec 2024<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -42.67%, with a dividend return of 0%, resulting in a total return of -42.67%.<BR><BR>Over the past year, the price return was -22.47%, the dividend return was 0.09%, leading to a total return of -22.38%.<BR><BR>In the 2-year period, the price return was 42.53%, with a dividend return of 0.19%, resulting in a total return of 42.72%.<BR><BR>For the 3-year period, the price return was 472.63%, the dividend return was 0.71%, culminating in a total return of 473.34%.<BR><BR>In the last 4 years, the price return was 962.85%, with a dividend return of 2.39%, leading to a total return of 965.24%.<BR><BR>Over the past 5 years, the price return was 686.51%, with a dividend return of 2.09%, resulting in a total return of 688.6%.<BR><BR>Overall, while Indo US Bio-Tech has declared a dividend, the recent total returns show significant volatility, particularly in the shorter periods, indicating a challenging performance in the near term despite positive long-term returns.